Voyager Therapeutics (NASDAQ:VYGR) Shares Down 1.1%

Voyager Therapeutics, Inc. (NASDAQ:VYGR)’s share price fell 1.1% during trading on Tuesday . The stock traded as low as $8.07 and last traded at $8.15. 97,338 shares changed hands during mid-day trading, a decline of 90% from the average session volume of 934,279 shares. The stock had previously closed at $8.24.

Analyst Upgrades and Downgrades

Several research firms recently commented on VYGR. HC Wainwright began coverage on Voyager Therapeutics in a research note on Tuesday, March 19th. They issued a “buy” rating and a $30.00 price objective on the stock. Wells Fargo & Company upgraded Voyager Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $9.00 to $14.00 in a research note on Tuesday, January 2nd. Citigroup initiated coverage on Voyager Therapeutics in a research report on Thursday, March 7th. They set a “buy” rating and a $16.00 target price on the stock. StockNews.com upgraded Voyager Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, March 9th. Finally, Guggenheim initiated coverage on Voyager Therapeutics in a research report on Tuesday, March 26th. They set a “buy” rating and a $22.00 target price on the stock. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $19.33.

Voyager Therapeutics Stock Down 3.0 %

The stock has a market cap of $420.28 million, a PE ratio of 2.50 and a beta of 0.96. The firm has a 50-day simple moving average of $8.79 and a 200-day simple moving average of $7.95.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings data on Wednesday, February 28th. The company reported $1.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $1.84. Voyager Therapeutics had a return on equity of 63.89% and a net margin of 52.93%. The company had revenue of $90.06 million for the quarter, compared to the consensus estimate of $4.95 million. On average, research analysts expect that Voyager Therapeutics, Inc. will post -1.64 earnings per share for the current year.

Institutional Investors Weigh In On Voyager Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Armistice Capital LLC raised its position in Voyager Therapeutics by 1.4% during the fourth quarter. Armistice Capital LLC now owns 4,236,000 shares of the company’s stock valued at $35,752,000 after purchasing an additional 58,000 shares in the last quarter. Vanguard Group Inc. raised its position in Voyager Therapeutics by 1.9% during the fourth quarter. Vanguard Group Inc. now owns 2,529,668 shares of the company’s stock valued at $21,350,000 after purchasing an additional 47,711 shares in the last quarter. BlackRock Inc. increased its holdings in shares of Voyager Therapeutics by 200.7% in the second quarter. BlackRock Inc. now owns 2,477,400 shares of the company’s stock worth $28,366,000 after buying an additional 1,653,613 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of Voyager Therapeutics by 19.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 932,231 shares of the company’s stock worth $7,869,000 after buying an additional 153,291 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its holdings in shares of Voyager Therapeutics by 13.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 901,465 shares of the company’s stock worth $6,951,000 after buying an additional 104,144 shares during the period. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.